A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Doxorubicin (Primary) ; Olaratumab (Primary)
  • Indications Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ANNOUNCE
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Aug 2017 Planned End Date changed from 1 Sep 2020 to 1 Jan 2020.
    • 25 Aug 2017 Planned primary completion date changed from 1 Mar 2019 to 1 Jan 2019.
    • 22 Nov 2016 Planned End Date changed from 1 Feb 2019 to 1 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top